The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.
Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.
Your daily dose of the clinical news you may have missed.
A 5-year study conducted in Germany showed only 7% of adults and 8% of children with severe anaphylaxis received epinephrine.
Your daily dose of the clinical news you may have missed.
Among pediatric patients aged 1 month to 18 years with emergent anaphylaxis, cephalosporins were the leading antibiotics and ibuprofen the top NSAID implicated in a new study.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.